HC Wainwright Lifts Earnings Estimates for PDS Biotechnology

PDS Biotechnology Corporation (NASDAQ:PDSB) – Stock analysts at HC Wainwright boosted their FY2026 EPS estimates for shares of PDS Biotechnology in a note issued to investors on Tuesday, March 31st. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.71) for the year, up from their prior estimate of ($0.73). The consensus estimate for PDS Biotechnology’s current full-year earnings is ($1.20) per share. HC Wainwright also issued estimates for PDS Biotechnology’s FY2027 earnings at ($0.77) EPS and FY2028 earnings at ($0.63) EPS.

PDS Biotechnology (NASDAQ:PDSB) last issued its quarterly earnings data on Monday, March 30th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.06.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of PDS Biotechnology in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $9.00.

PDS Biotechnology Price Performance

NASDAQ PDSB opened at $0.61 on Thursday. PDS Biotechnology has a fifty-two week low of $0.51 and a fifty-two week high of $1.92. The stock’s 50-day moving average is $0.70 and its two-hundred day moving average is $0.85. The firm has a market cap of $31.75 million, a P/E ratio of -0.81 and a beta of 1.20. The company has a debt-to-equity ratio of 1.26, a current ratio of 2.09 and a quick ratio of 2.09.

Institutional Trading of PDS Biotechnology

A number of institutional investors and hedge funds have recently modified their holdings of PDSB. Armistice Capital LLC bought a new stake in shares of PDS Biotechnology during the 4th quarter worth $2,182,000. Geode Capital Management LLC lifted its position in PDS Biotechnology by 8.0% during the 4th quarter. Geode Capital Management LLC now owns 520,398 shares of the company’s stock worth $401,000 after acquiring an additional 38,399 shares during the last quarter. Inspirion Wealth Advisors LLC lifted its position in PDS Biotechnology by 338.5% during the 3rd quarter. Inspirion Wealth Advisors LLC now owns 344,394 shares of the company’s stock worth $348,000 after acquiring an additional 265,862 shares during the last quarter. Squarepoint Ops LLC boosted its holdings in PDS Biotechnology by 116.1% during the third quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock valued at $295,000 after acquiring an additional 156,662 shares during the period. Finally, Commonwealth Equity Services LLC boosted its holdings in PDS Biotechnology by 117.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock valued at $151,000 after acquiring an additional 106,300 shares during the period. 26.84% of the stock is currently owned by institutional investors and hedge funds.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.